Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04491084 · ClinicalTrials.gov registry record · Phase 1
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04491084 is a Phase 1 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 5 participants.
The verdict
NCT04491084, a Phase 1 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.
Interventions
- RADIATION SBRT
- DRUG FLT3 Ligand (CDX-301)
- BIOLOGICAL anti-CD40 antibody (CDX-1140)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2022-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04491084
The ClinicalTrials.gov registry entry for NCT04491084 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SBRT is the first listed.
NCT04491084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04491084 about?
NCT04491084 is a clinical study titled "FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy". The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treat...
What is the current status of trial NCT04491084?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-01-01. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT04491084?
The interventions under investigation include: SBRT (RADIATION), FLT3 Ligand (CDX-301) (DRUG), anti-CD40 antibody (CDX-1140) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04491084?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.